Oxford Bioscience Partners

Yolia Health is a medical equipment company based in Mexico City, specializing in innovative solutions for vision correction. The company has developed the True Vision Treatment (TVT), a non-invasive method designed to address vision problems such as presbyopia, myopia, and hyperopia. The treatment combines customized contact lenses and specially formulated eye drops, allowing patients to self-administer the therapy at home. After a brief treatment period of five days, patients can often forgo the use of contact lenses, eye drops, and reading glasses for up to twelve months before needing re-treatment. Yolia Health's approach uniquely improves both near and distance vision without compromising the latter, distinguishing it from other alternatives in the market.

CardioFocus, Inc. is a biotechnology company specializing in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. Founded in 1990 and headquartered in Marlborough, Massachusetts, the company has created advanced endoscopic ablation systems that enhance precision and control during medical procedures. Its flagship product, the HeartLight Endoscopic Ablation System, utilizes laser balloon technology to achieve consistent pulmonary vein isolation, crucial for managing paroxysmal atrial fibrillation. Additionally, the HeartLight Excalibur Balloon offers clinicians the ability to maintain stable contact with direct visualization for effective lesion creation, while the HeartLight X3 System provides a mode for controlled lesion development. CardioFocus aims to equip electrophysiologists with tools that improve treatment outcomes through enhanced visualization and customizable energy delivery, addressing the specific needs of patients undergoing ablation procedures.

Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.

Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

Mitralign is a privately held medical device company based in a suburb of Boston, Massachusetts. It specializes in developing catheter-based technologies for the percutaneous treatment of functional mitral regurgitation, a global and life-threatening cardiac condition. The company's innovative Mitralign system mimics surgical annuloplasty by delivering a series of implants directly into the mitral annulus via a catheter, reducing its size and improving valve function. Mitralign is backed by top-tier venture capitalists and has strategic investments from major cardiovascular device companies.

Glori Energy Inc is a development stage company focused on enhancing oil recovery from existing well reservoirs without the need for new drilling. The company collaborates with oil producers to implement its proprietary AEROTM (Activated Environment for Recovery of Oil) System, which aims to significantly boost oil production. This innovative system provides a low-cost and environmentally friendly solution for recovering billions of barrels of oil that were previously trapped, thereby facilitating a more sustainable approach to oil extraction.

CardioFocus, Inc. is a biotechnology company specializing in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. Founded in 1990 and headquartered in Marlborough, Massachusetts, the company has created advanced endoscopic ablation systems that enhance precision and control during medical procedures. Its flagship product, the HeartLight Endoscopic Ablation System, utilizes laser balloon technology to achieve consistent pulmonary vein isolation, crucial for managing paroxysmal atrial fibrillation. Additionally, the HeartLight Excalibur Balloon offers clinicians the ability to maintain stable contact with direct visualization for effective lesion creation, while the HeartLight X3 System provides a mode for controlled lesion development. CardioFocus aims to equip electrophysiologists with tools that improve treatment outcomes through enhanced visualization and customizable energy delivery, addressing the specific needs of patients undergoing ablation procedures.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

Adastra Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in developing innovative treatments for cancer. Founded in 2005 and previously known as Tragara Pharmaceuticals, the company is focused on creating proprietary medicines aimed at improving patient care in oncology. Among its key products is an oral multi-kinase inhibitor designed to inhibit critical cyclin-dependent kinases, which may enhance patient survival rates and overall quality of life. Adastra Pharmaceuticals is dedicated to advancing its portfolio of cancer therapies to meet the needs of healthcare professionals and patients alike.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

Molecular Biometrics, Inc. is a metabolomics company based in Norwood, Massachusetts, established in 2005. The company specializes in developing innovative, non-invasive methodologies that utilize novel metabolomic technologies to assess normal biological functions related to health and disease, as well as to facilitate drug discovery and development. Its proprietary technology has applications in various medical fields, including reproductive health, neurodegenerative diseases such as Alzheimer's and Parkinson's, maternal-fetal medicine, as well as pulmonary metabolism and edema, and lactate metabolism. Through its focus on metabolomics, Molecular Biometrics aims to enhance understanding and evaluation of biological processes and improve clinical outcomes.

ImpactRx, Inc. is a promotion research organization serving the pharmaceutical industry in the United States. The company specializes in tracking and evaluating the effects of pharmaceutical promotions on physicians' prescribing behaviors. Utilizing its proprietary technology, ImpactRx collects and processes data regarding physicians' perceptions and activities, enabling pharmaceutical companies to assess and predict the effectiveness of their sales and marketing initiatives. The organization offers a variety of syndicated and semi-custom products focused on brand management, market research, sales management, managed care marketing, and oncology sales and marketing. These services support pharmaceutical and biotech companies in making informed decisions. Founded in 2000, ImpactRx is headquartered in Mount Laurel, New Jersey.

CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps designed for long-term partial circulatory support. Its proprietary micro-pump platform allows for the creation of compact devices that can be implanted in a superficial pocket, similar to a pacemaker, utilizing endovascular or minimally-invasive surgical techniques. By supplementing a patient's natural heart function, CircuLite aims to provide a proactive and lower-risk treatment option, thereby enhancing the quality of life for millions of individuals suffering from chronic heart failure. The company’s flagship product, the Synergy Pocket Circulatory Assist Device, is designed to rest a failing heart while supporting its natural pumping capacity.

Cambrios Technologies Corporation is a manufacturer of innovative electronic materials specializing in silver nanowire-based electrodes. Founded in 2002 and originally named Semzyme, Inc., the company rebranded in August 2004. Headquartered in Sunnyvale, California, with additional offices in Japan and Taiwan, Cambrios develops products such as ClearOhm, which are transparent conductive coatings that can be applied to various substrates for multiple applications. These include touch screens, liquid crystal displays, e-paper, OLED devices, and lighting, as well as thin film photovoltaics like organic photovoltaics and printed organic solar cells. Cambrios's technology enables simplified manufacturing processes and enhances the performance of next-generation consumer devices.

Coherex Medical, Inc. is a medical device company based in Salt Lake City, Utah, focused on developing and marketing catheter-based technologies for the treatment of structural heart defects. Founded in 2003 as Proximare, Inc., the company rebranded in 2006 to its current name. Coherex Medical specializes in devices designed for patients with atrial fibrillation, aiming to reduce the risk of stroke. Its product offerings include a patent foramen ovale (PFO) closure system that promotes tissue in-growth for long-term closure and a WaveCrest device intended to close the left atrial appendage, enhancing the safety and simplicity of implant procedures. The company serves both domestic and international markets, providing innovative solutions for addressing structural heart disease.

VaxInnate is a vaccine company founded in 2002 and headquartered in Cranbury, New Jersey, that specializes in developing vaccines for various infectious diseases, including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. The company utilizes a unique technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, enhancing the immunogenicity and efficacy of its vaccines. This innovative approach allows for quicker treatment initiation, increasing the likelihood of successful patient outcomes. VaxInnate operates within the healthcare, health diagnostics, and biotechnology sectors, focusing on advancing vaccine development to address significant global health challenges.

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Claros Diagnostics Inc., established in 2015, specializes in developing portable immunoassay systems designed for point-of-care blood testing. Their innovative product comprises a handheld analyzer and disposable cassettes capable of detecting multiple biomarkers simultaneously. This technology enables healthcare professionals and patients to conduct tests for infectious diseases, cancer, and immune disorders outside traditional laboratory settings.

Seahorse Bioscience specializes in providing analytical instruments, biomanufacturing systems, and consumable labware for biological research and drug discovery. The company is known for its Seahorse extracellular flux (XF) analyzers, which allow for non-invasive profiling of cellular metabolic activity. These instruments enable researchers to assess key metabolic parameters, such as basal oxygen consumption, glycolysis rates, ATP turnover, and respiratory capacity, thereby facilitating the study of mitochondrial dysfunction. Seahorse Bioscience serves a diverse clientele, including scientists at academic institutions, pharmaceutical and biotech companies, and original equipment manufacturers of assay kits and laboratory instruments.

Pathway Medical Technologies Inc. specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative atherectomy catheter, which is engineered to restore circulation in peripheral arteries by effectively removing hard and soft plaque, calcium deposits, thrombus, and fibrotic lesions. Accompanying this device is a control pod that offers a user-friendly interface with keypad controls for seamless operation. Pathway Medical Technologies is dedicated to providing safe and effective treatment options for patients suffering from arterial diseases.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

LUCA Technologies is developing long-term, biotechnology-driven solutions to rising U.S. dependence on foreign energy sources. Addressing the $150 billion domestic natural gas market, the company is leveraging the ability of naturally occurring microorganisms to convert under-utilized domestic oil, organic-rich shale and coal resources to clean, renewable energy. The company initially expects to provide consulting services to existing energy producers, helping them to evaluate their current oil, organic-rich shale and gas holdings for the presence of natural Geobioreactors or the potential for Geobioreactor stimulation.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Molecular Biometrics, Inc. is a metabolomics company based in Norwood, Massachusetts, established in 2005. The company specializes in developing innovative, non-invasive methodologies that utilize novel metabolomic technologies to assess normal biological functions related to health and disease, as well as to facilitate drug discovery and development. Its proprietary technology has applications in various medical fields, including reproductive health, neurodegenerative diseases such as Alzheimer's and Parkinson's, maternal-fetal medicine, as well as pulmonary metabolism and edema, and lactate metabolism. Through its focus on metabolomics, Molecular Biometrics aims to enhance understanding and evaluation of biological processes and improve clinical outcomes.

Dicerna Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of RNA interference (RNAi)-based therapeutics. The company focuses on innovative treatments for rare inherited liver diseases, viral infections, chronic liver diseases, and cardiometabolic conditions. Utilizing its proprietary GalXC RNAi technology platform, Dicerna is advancing several key product candidates, including nedosiran for primary hyperoxaluria, RG6346 for chronic hepatitis B, and programs targeting genetic liver diseases and cardiovascular conditions. Founded in 2007 and headquartered in Lexington, Massachusetts, Dicerna has established strategic collaborations with major pharmaceutical firms to enhance its research and development efforts.

ZettaCore is at the forefront of molecular electronics, dedicated to creating advanced molecular materials tailored for the electronics industry. By utilizing innovative chemistry, the company enhances existing manufacturing processes, facilitating a shift towards improved performance while simultaneously reducing costs.

BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.

Laboratory Partners, Inc. provides clinical diagnostic testing services for healthcare providers, including both hospitals and private practices. Laboratory Partners, Inc. is based in Palo Alto, California.

HydroCision, Inc. is a medical device company specializing in the development and commercialization of fluid jet-based surgical tools, particularly for the spine market. Founded in 1994 and headquartered in North Billerica, Massachusetts, the company offers innovative products such as the TenJet System, which utilizes ultrasound guidance for the percutaneous treatment of chronic tendon pain across various applications, and the SpineJet HydroDiscectomy System, designed for minimally invasive disc decompression procedures without the risks associated with thermal energy. Additional offerings include the SpineJet Fusion System, which prepares intervertebral disc spaces for graft implantation, and the AlloJet system for soft tissue debridement from donor bones. HydroCision’s technology enables precise tissue removal while minimizing damage to surrounding structures, thereby improving surgical outcomes. The company serves hospitals and physicians through its dedicated sales representatives.

Mitralign is a privately held medical device company based in a suburb of Boston, Massachusetts. It specializes in developing catheter-based technologies for the percutaneous treatment of functional mitral regurgitation, a global and life-threatening cardiac condition. The company's innovative Mitralign system mimics surgical annuloplasty by delivering a series of implants directly into the mitral annulus via a catheter, reducing its size and improving valve function. Mitralign is backed by top-tier venture capitalists and has strategic investments from major cardiovascular device companies.

Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.

Courtagen Life Sciences, Inc. is a biotechnology company based in Woburn, Massachusetts, specializing in genetic testing services. The company provides a range of clinical genetic tests focused on neurological conditions, including developmental delay, intellectual disability, autism spectrum disorders, epilepsy, and mitochondrial disorders. Its offerings include comprehensive analyses such as epiSEEK Comprehensive and epiSEEK Focus, which assess genes associated with neurological function and seizure disorders, respectively. Additionally, Courtagen offers tests for drug metabolism related to epilepsy, as well as panels for neurodevelopmental and lysosomal storage disorders. The company also provides next generation sequencing services to support research in target discovery, clinical development, and companion diagnostics. Founded in 2003, Courtagen Life Sciences aims to empower physicians, families, and children affected by neurological disorders through advanced genetic insights.

Xencor, Inc. is a clinical-stage biopharmaceutical company headquartered in Monrovia, California, specializing in the discovery and development of engineered monoclonal antibodies and other protein therapeutics aimed at treating severe and life-threatening diseases. The company leverages its proprietary XmAb technology platform to create a range of antibody product candidates for various conditions, including cancer and autoimmune diseases. Notable candidates in its portfolio include XmAb5871 and AIMab7195, both targeting autoimmune disorders, and several bispecific antibodies currently in clinical trials, such as XmAb14045 for acute myeloid leukemia and plamotamab for B-cell malignancies. Additionally, Xencor is advancing therapies for neuroendocrine tumors and gastrointestinal stromal tumors, as well as developing preclinical bispecific antibodies for various cancers. The company generates revenue through research and development collaborations and licensing agreements with major pharmaceutical firms. Founded in 1997, Xencor is committed to addressing unmet medical needs through innovative therapeutic solutions.

LUCA Technologies is developing long-term, biotechnology-driven solutions to rising U.S. dependence on foreign energy sources. Addressing the $150 billion domestic natural gas market, the company is leveraging the ability of naturally occurring microorganisms to convert under-utilized domestic oil, organic-rich shale and coal resources to clean, renewable energy. The company initially expects to provide consulting services to existing energy producers, helping them to evaluate their current oil, organic-rich shale and gas holdings for the presence of natural Geobioreactors or the potential for Geobioreactor stimulation.

Paperspace is a cloud computing company that specializes in machine learning (ML) development. It offers a high-performance cloud platform for building, training, and deploying ML models, catering to individuals, startups, and enterprises. The platform provides a cloud-based personal computer accessible via any web browser, making cloud computing more accessible through simplicity, community-driven resources, and straightforward pricing. This enables users to iterate faster and collaborate on real-time prediction engines.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

Intechra, LLC is an electronics lifecycle management company based in Jackson, Mississippi, specializing in information technology asset disposition, value recovery, and computer recycling services for businesses and government entities. Founded in 1987, the company assists organizations in retiring IT assets such as personal computers, servers, and networking equipment, while ensuring compliance with federal privacy regulations and environmental laws. Intechra offers a range of services, including data security, logistics support with secured transport and chain of custody, and on-site services. Additionally, the company recycles various materials, including metals, circuit boards, batteries, and plastics. Intechra also operates an online store that sells laptops, personal computers, and computer parts, catering primarily to small and mid-sized businesses, cities, and educational institutions.

CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps designed for long-term partial circulatory support. Its proprietary micro-pump platform allows for the creation of compact devices that can be implanted in a superficial pocket, similar to a pacemaker, utilizing endovascular or minimally-invasive surgical techniques. By supplementing a patient's natural heart function, CircuLite aims to provide a proactive and lower-risk treatment option, thereby enhancing the quality of life for millions of individuals suffering from chronic heart failure. The company’s flagship product, the Synergy Pocket Circulatory Assist Device, is designed to rest a failing heart while supporting its natural pumping capacity.

Coherex Medical, Inc. is a medical device company based in Salt Lake City, Utah, focused on developing and marketing catheter-based technologies for the treatment of structural heart defects. Founded in 2003 as Proximare, Inc., the company rebranded in 2006 to its current name. Coherex Medical specializes in devices designed for patients with atrial fibrillation, aiming to reduce the risk of stroke. Its product offerings include a patent foramen ovale (PFO) closure system that promotes tissue in-growth for long-term closure and a WaveCrest device intended to close the left atrial appendage, enhancing the safety and simplicity of implant procedures. The company serves both domestic and international markets, providing innovative solutions for addressing structural heart disease.

Nfocus Neuromedical, Inc. designs, develops, and markets endovascular neurosurgery solutions to cure intracranial aneurysms. The company offers revolutionary systems to treat neurovascular disease, including brain aneurysms. The company was formerly known as CardioVasc, Inc. and changed its name to Nfocus Neuromedical, Inc. in April 2007. The company was incorporated in 1997 and is based in Palo Alto, California. As of February 19, 2013, Nfocus Neuromedical, Inc. operates as a subsidiary of Covidien plc.

Cambrios Technologies Corporation is a manufacturer of innovative electronic materials specializing in silver nanowire-based electrodes. Founded in 2002 and originally named Semzyme, Inc., the company rebranded in August 2004. Headquartered in Sunnyvale, California, with additional offices in Japan and Taiwan, Cambrios develops products such as ClearOhm, which are transparent conductive coatings that can be applied to various substrates for multiple applications. These include touch screens, liquid crystal displays, e-paper, OLED devices, and lighting, as well as thin film photovoltaics like organic photovoltaics and printed organic solar cells. Cambrios's technology enables simplified manufacturing processes and enhances the performance of next-generation consumer devices.

Radius Health, Inc. is a biopharmaceutical company specializing in the development and commercialization of endocrine therapeutics, particularly targeting osteoporosis and oncology. The company markets TYMLOS, an anabolic agent aimed at treating postmenopausal women with osteoporosis. In addition to TYMLOS, Radius is advancing several clinical candidates, including abaloparatide-SC for men with osteoporosis, a transdermal patch for postmenopausal women, Elacestrant for hormone receptor-positive breast cancer, and RAD140 for metastatic breast cancer. Founded in 2003 and headquartered in Waltham, Massachusetts, Radius collaborates with various organizations, including 3M Company and Ipsen Pharma, to enhance its research and development efforts. The company is committed to addressing unmet medical needs in bone health and women's health, with a long-term vision of expanding its therapeutic focus.

Affinium Pharmaceuticals is a specialty pharmaceutical company dedicated to developing innovative anti-infective medications. The company focuses on its FASII antibacterial programs, which represent a new franchise of antibiotics targeting the FASII pathway. These programs are supported by a robust portfolio of intellectual property, including both issued and pending patents for potent orally available small molecule inhibitors. Affinium's unique approach aims to address the growing need for effective antibiotics by targeting an underexploited mechanism of action, positioning the company at the forefront of the fight against resistant infections.

Adastra Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, that specializes in developing innovative treatments for cancer. Founded in 2005 and previously known as Tragara Pharmaceuticals, the company is focused on creating proprietary medicines aimed at improving patient care in oncology. Among its key products is an oral multi-kinase inhibitor designed to inhibit critical cyclin-dependent kinases, which may enhance patient survival rates and overall quality of life. Adastra Pharmaceuticals is dedicated to advancing its portfolio of cancer therapies to meet the needs of healthcare professionals and patients alike.

Claros Diagnostics Inc., established in 2015, specializes in developing portable immunoassay systems designed for point-of-care blood testing. Their innovative product comprises a handheld analyzer and disposable cassettes capable of detecting multiple biomarkers simultaneously. This technology enables healthcare professionals and patients to conduct tests for infectious diseases, cancer, and immune disorders outside traditional laboratory settings.

CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps designed for long-term partial circulatory support. Its proprietary micro-pump platform allows for the creation of compact devices that can be implanted in a superficial pocket, similar to a pacemaker, utilizing endovascular or minimally-invasive surgical techniques. By supplementing a patient's natural heart function, CircuLite aims to provide a proactive and lower-risk treatment option, thereby enhancing the quality of life for millions of individuals suffering from chronic heart failure. The company’s flagship product, the Synergy Pocket Circulatory Assist Device, is designed to rest a failing heart while supporting its natural pumping capacity.

HydroCision, Inc. is a medical device company specializing in the development and commercialization of fluid jet-based surgical tools, particularly for the spine market. Founded in 1994 and headquartered in North Billerica, Massachusetts, the company offers innovative products such as the TenJet System, which utilizes ultrasound guidance for the percutaneous treatment of chronic tendon pain across various applications, and the SpineJet HydroDiscectomy System, designed for minimally invasive disc decompression procedures without the risks associated with thermal energy. Additional offerings include the SpineJet Fusion System, which prepares intervertebral disc spaces for graft implantation, and the AlloJet system for soft tissue debridement from donor bones. HydroCision’s technology enables precise tissue removal while minimizing damage to surrounding structures, thereby improving surgical outcomes. The company serves hospitals and physicians through its dedicated sales representatives.

HydroCision, Inc. is a medical device company specializing in the development and commercialization of fluid jet-based surgical tools, particularly for the spine market. Founded in 1994 and headquartered in North Billerica, Massachusetts, the company offers innovative products such as the TenJet System, which utilizes ultrasound guidance for the percutaneous treatment of chronic tendon pain across various applications, and the SpineJet HydroDiscectomy System, designed for minimally invasive disc decompression procedures without the risks associated with thermal energy. Additional offerings include the SpineJet Fusion System, which prepares intervertebral disc spaces for graft implantation, and the AlloJet system for soft tissue debridement from donor bones. HydroCision’s technology enables precise tissue removal while minimizing damage to surrounding structures, thereby improving surgical outcomes. The company serves hospitals and physicians through its dedicated sales representatives.

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Solstice Neurosciences is a specialty biopharmaceutical company dedicated to the development, manufacturing, sales, and marketing of biopharmaceutical products. The company's primary offering is Myobloc (rimabotulinumtoxinB) Injection, known as NeuroBloc in select international markets, which is the only botulinum toxin type B available to healthcare professionals and patients worldwide. This injectable solution is specifically designed for the treatment of cervical dystonia, helping to alleviate the severity of abnormal head positions and associated pain. In addition to its product line, Solstice Neurosciences provides comprehensive support services, including reimbursement assistance, product support, and access to medical information. The company also operates MYOBLOC University, an online educational resource aimed at enhancing physician knowledge through innovative learning technologies.

Pathway Medical Technologies Inc. specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative atherectomy catheter, which is engineered to restore circulation in peripheral arteries by effectively removing hard and soft plaque, calcium deposits, thrombus, and fibrotic lesions. Accompanying this device is a control pod that offers a user-friendly interface with keypad controls for seamless operation. Pathway Medical Technologies is dedicated to providing safe and effective treatment options for patients suffering from arterial diseases.

VaxInnate is a vaccine company founded in 2002 and headquartered in Cranbury, New Jersey, that specializes in developing vaccines for various infectious diseases, including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. The company utilizes a unique technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, enhancing the immunogenicity and efficacy of its vaccines. This innovative approach allows for quicker treatment initiation, increasing the likelihood of successful patient outcomes. VaxInnate operates within the healthcare, health diagnostics, and biotechnology sectors, focusing on advancing vaccine development to address significant global health challenges.

Mitralign is a privately held medical device company based in a suburb of Boston, Massachusetts. It specializes in developing catheter-based technologies for the percutaneous treatment of functional mitral regurgitation, a global and life-threatening cardiac condition. The company's innovative Mitralign system mimics surgical annuloplasty by delivering a series of implants directly into the mitral annulus via a catheter, reducing its size and improving valve function. Mitralign is backed by top-tier venture capitalists and has strategic investments from major cardiovascular device companies.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of small molecule drugs aimed at addressing unmet medical needs in central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, the company is best known for NUPLAZID (pimavanserin), which is approved for treating hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA is also advancing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive therapy for schizophrenia, both of which are currently in Phase III clinical trials. Additionally, the company is exploring the use of pimavanserin for major depressive disorder. ACADIA maintains subsidiaries in Sweden and Denmark and is focused on expanding its portfolio of drug candidates, seeking to discover innovative therapies for various neurological and psychiatric conditions.

Courtagen Life Sciences, Inc. is a biotechnology company based in Woburn, Massachusetts, specializing in genetic testing services. The company provides a range of clinical genetic tests focused on neurological conditions, including developmental delay, intellectual disability, autism spectrum disorders, epilepsy, and mitochondrial disorders. Its offerings include comprehensive analyses such as epiSEEK Comprehensive and epiSEEK Focus, which assess genes associated with neurological function and seizure disorders, respectively. Additionally, Courtagen offers tests for drug metabolism related to epilepsy, as well as panels for neurodevelopmental and lysosomal storage disorders. The company also provides next generation sequencing services to support research in target discovery, clinical development, and companion diagnostics. Founded in 2003, Courtagen Life Sciences aims to empower physicians, families, and children affected by neurological disorders through advanced genetic insights.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to the development and commercialization of innovative products aimed at treating mitochondrial and neuromuscular diseases. This field encompasses numerous orphan and niche indications with significant unmet medical needs and limited existing therapies. The company's operations primarily focus on neuro-ophthalmological, pulmonary, and neuromuscular conditions. Santhera generates a substantial portion of its revenue from the European Union, leveraging its expertise to address critical health challenges in these specialized areas.

Hypnion is a neuroscience drug discovery and development company based in Worcester, Massachusetts, founded in 2000. The company specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness disorders, as well as circadian rhythm abnormalities. Hypnion utilizes its proprietary drug discovery platform, SCORE-2004, which measures the effects of drugs on sleep and wake parameters. This unique system enables the company to advance its research and development efforts effectively. In recognition of its innovative approach and contributions to the field, Hypnion was acquired by Eli Lilly and Company.

FlowMedica is a medical device company specializing in intravascular systems for Targeted Renal Therapy. The company develops innovative solutions aimed at addressing kidney dysfunction associated with cardiovascular disease, cancer, and surgical procedures. Its flagship product, the Benephit CV Infusion System, enables physicians to deliver therapeutic agents directly into the renal arteries through an infusion catheter, facilitating simultaneous coronary procedures via a single access point in the femoral artery. Additionally, the Benephit XTMini Infusion System caters to patients with smaller vascular anatomies by allowing bilateral infusion to the kidneys. FlowMedica's devices present a precise alternative to traditional systemic intravenous infusion methods, enabling surgeons to administer treatments directly and accurately.

BrainCells develops and provides biopharmaceutical products for the treatment of central nervous system (CNS) diseases. It develops compounds that promote the growth of new neurons for the treatment of major depressive disorder (MDD), treatment resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's products include BCI-838 and BCI-632 which increase synaptic glutamate by inhibiting the mGlu2/3 auto-receptor. The company also builds a pipeline of clinical-stage programs to address unmet medical needs in the treatment of mood disorders, psychoses, cognition, brain repair syndromes, and other CNS disorders. The company was founded in 2003 and is based in San Diego, California.

Solstice Neurosciences is a specialty biopharmaceutical company dedicated to the development, manufacturing, sales, and marketing of biopharmaceutical products. The company's primary offering is Myobloc (rimabotulinumtoxinB) Injection, known as NeuroBloc in select international markets, which is the only botulinum toxin type B available to healthcare professionals and patients worldwide. This injectable solution is specifically designed for the treatment of cervical dystonia, helping to alleviate the severity of abnormal head positions and associated pain. In addition to its product line, Solstice Neurosciences provides comprehensive support services, including reimbursement assistance, product support, and access to medical information. The company also operates MYOBLOC University, an online educational resource aimed at enhancing physician knowledge through innovative learning technologies.

Mitralign is a privately held medical device company based in a suburb of Boston, Massachusetts. It specializes in developing catheter-based technologies for the percutaneous treatment of functional mitral regurgitation, a global and life-threatening cardiac condition. The company's innovative Mitralign system mimics surgical annuloplasty by delivering a series of implants directly into the mitral annulus via a catheter, reducing its size and improving valve function. Mitralign is backed by top-tier venture capitalists and has strategic investments from major cardiovascular device companies.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

Alantos Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule drugs targeting osteoarthritis, inflammation, and type II diabetes. Founded in 2002 and based in Cambridge, Massachusetts, the company specializes in creating innovative therapies, including Dipeptidyl and Peptidase IV inhibitors. Alantos also explores various tissue remodeling pathways to address conditions such as rheumatoid arthritis, liver fibrosis, cardiovascular issues, chronic wound healing, and cancer. Through its research and development efforts, Alantos Pharmaceuticals aims to advance treatment options for patients suffering from these chronic diseases.

Pathway Medical Technologies Inc. specializes in the design, development, manufacturing, and marketing of medical devices aimed at treating arterial and vascular diseases. The company focuses on addressing peripheral arterial disease through its innovative atherectomy catheter, which is engineered to restore circulation in peripheral arteries by effectively removing hard and soft plaque, calcium deposits, thrombus, and fibrotic lesions. Accompanying this device is a control pod that offers a user-friendly interface with keypad controls for seamless operation. Pathway Medical Technologies is dedicated to providing safe and effective treatment options for patients suffering from arterial diseases.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of small molecule drugs aimed at addressing unmet medical needs in central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, the company is best known for NUPLAZID (pimavanserin), which is approved for treating hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA is also advancing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive therapy for schizophrenia, both of which are currently in Phase III clinical trials. Additionally, the company is exploring the use of pimavanserin for major depressive disorder. ACADIA maintains subsidiaries in Sweden and Denmark and is focused on expanding its portfolio of drug candidates, seeking to discover innovative therapies for various neurological and psychiatric conditions.

Cambrios Technologies Corporation is a manufacturer of innovative electronic materials specializing in silver nanowire-based electrodes. Founded in 2002 and originally named Semzyme, Inc., the company rebranded in August 2004. Headquartered in Sunnyvale, California, with additional offices in Japan and Taiwan, Cambrios develops products such as ClearOhm, which are transparent conductive coatings that can be applied to various substrates for multiple applications. These include touch screens, liquid crystal displays, e-paper, OLED devices, and lighting, as well as thin film photovoltaics like organic photovoltaics and printed organic solar cells. Cambrios's technology enables simplified manufacturing processes and enhances the performance of next-generation consumer devices.

CircuLite is a cardiovascular device company focused on transforming the treatment of heart failure through the development of minimally-invasive micro-pumps designed for long-term partial circulatory support. Its proprietary micro-pump platform allows for the creation of compact devices that can be implanted in a superficial pocket, similar to a pacemaker, utilizing endovascular or minimally-invasive surgical techniques. By supplementing a patient's natural heart function, CircuLite aims to provide a proactive and lower-risk treatment option, thereby enhancing the quality of life for millions of individuals suffering from chronic heart failure. The company’s flagship product, the Synergy Pocket Circulatory Assist Device, is designed to rest a failing heart while supporting its natural pumping capacity.

FlowMedica is a medical device company specializing in intravascular systems for Targeted Renal Therapy. The company develops innovative solutions aimed at addressing kidney dysfunction associated with cardiovascular disease, cancer, and surgical procedures. Its flagship product, the Benephit CV Infusion System, enables physicians to deliver therapeutic agents directly into the renal arteries through an infusion catheter, facilitating simultaneous coronary procedures via a single access point in the femoral artery. Additionally, the Benephit XTMini Infusion System caters to patients with smaller vascular anatomies by allowing bilateral infusion to the kidneys. FlowMedica's devices present a precise alternative to traditional systemic intravenous infusion methods, enabling surgeons to administer treatments directly and accurately.

Solexa engages in developing and commercializing genetic analysis technologies primarily in the United States and the United Kingdom. The company is developing and preparing Solexa Genome Analysis System, which performs DNA sequencing based on its proprietary reversible terminator Sequencing-by-Synthesis, chemistry, and Clonal Single Molecule Array technology. Its platform is designed to support a range of analyses, including whole genome resequencing, gene expression analysis, and small RNA analysis.

Courtagen Life Sciences, Inc. is a biotechnology company based in Woburn, Massachusetts, specializing in genetic testing services. The company provides a range of clinical genetic tests focused on neurological conditions, including developmental delay, intellectual disability, autism spectrum disorders, epilepsy, and mitochondrial disorders. Its offerings include comprehensive analyses such as epiSEEK Comprehensive and epiSEEK Focus, which assess genes associated with neurological function and seizure disorders, respectively. Additionally, Courtagen offers tests for drug metabolism related to epilepsy, as well as panels for neurodevelopmental and lysosomal storage disorders. The company also provides next generation sequencing services to support research in target discovery, clinical development, and companion diagnostics. Founded in 2003, Courtagen Life Sciences aims to empower physicians, families, and children affected by neurological disorders through advanced genetic insights.

Enanta Pharmaceuticals, Inc., established in 1998 and headquartered in Watertown, Massachusetts, is a biotechnology company dedicated to discovering and developing small molecule drugs for treating viral infections and liver diseases. Its primary focus areas include hepatitis C virus (HCV), hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV). Enanta offers glecaprevir, marketed as MAVYRET and MAVIRET, for chronic HCV treatment. Through a collaborative agreement with Abbott Laboratories, the company has developed paritaprevir, an HCV NS3/4A protease inhibitor. Enanta's pipeline also includes direct-acting antiviral inhibitors against HCV and other viral targets.

Cambrios Technologies Corporation is a manufacturer of innovative electronic materials specializing in silver nanowire-based electrodes. Founded in 2002 and originally named Semzyme, Inc., the company rebranded in August 2004. Headquartered in Sunnyvale, California, with additional offices in Japan and Taiwan, Cambrios develops products such as ClearOhm, which are transparent conductive coatings that can be applied to various substrates for multiple applications. These include touch screens, liquid crystal displays, e-paper, OLED devices, and lighting, as well as thin film photovoltaics like organic photovoltaics and printed organic solar cells. Cambrios's technology enables simplified manufacturing processes and enhances the performance of next-generation consumer devices.

IntraPace, Inc. is a medical device company focused on developing innovative solutions for obesity treatment. Founded in 2001 and headquartered in Mountain View, California, the company has created the abiliti system, an implantable device that stimulates a satiety response to assist patients in achieving weight loss. This device utilizes established technology similar to that found in cardiac pacemakers and defibrillators. The abiliti system is designed for implantation using standard laparoscopic techniques, allowing for a minimally invasive procedure that does not alter the anatomy of the digestive system or restrict dietary choices.

Trubion Pharmaceuticals is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. Our product candidates are novel proteins known as single-chain polypeptides and are designed using our SMIPTM custom drug assembly technology.

PowderMed developed vaccines for the treatment of chronic infectious diseases and cancer. The company used DNA coated gold particles delivered by a needle-free injection device to stimulate a powerful and specific T cell immune response.

Ensemble Therapeutics is a biopharmaceutical company based in Cambridge, Massachusetts, focused on discovering and developing innovative small molecule therapies for cancer and other serious diseases. The company's pipeline primarily emphasizes immuno-oncology programs, including targets like Indoleamine 2,3-dioxygenase 1 (IDO-1) and Ubiquitin-specific protease 9x. Additionally, Ensemble Therapeutics explores inhibitors of apoptosis proteins such as XIAP and cIAP, as well as Cyclophilins, which play roles in protein folding and cancer progression. The company aims to address drug targets that are typically considered inaccessible with conventional small molecule drugs, offering patients new treatment options.

Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.

Mitralign is a privately held medical device company based in a suburb of Boston, Massachusetts. It specializes in developing catheter-based technologies for the percutaneous treatment of functional mitral regurgitation, a global and life-threatening cardiac condition. The company's innovative Mitralign system mimics surgical annuloplasty by delivering a series of implants directly into the mitral annulus via a catheter, reducing its size and improving valve function. Mitralign is backed by top-tier venture capitalists and has strategic investments from major cardiovascular device companies.

VaxInnate is a vaccine company founded in 2002 and headquartered in Cranbury, New Jersey, that specializes in developing vaccines for various infectious diseases, including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus. The company utilizes a unique technology that involves genetically fusing vaccine antigens to the bacterial protein flagellin, enhancing the immunogenicity and efficacy of its vaccines. This innovative approach allows for quicker treatment initiation, increasing the likelihood of successful patient outcomes. VaxInnate operates within the healthcare, health diagnostics, and biotechnology sectors, focusing on advancing vaccine development to address significant global health challenges.

ZettaCore is at the forefront of molecular electronics, dedicated to creating advanced molecular materials tailored for the electronics industry. By utilizing innovative chemistry, the company enhances existing manufacturing processes, facilitating a shift towards improved performance while simultaneously reducing costs.

Enanta Pharmaceuticals, Inc., established in 1998 and headquartered in Watertown, Massachusetts, is a biotechnology company dedicated to discovering and developing small molecule drugs for treating viral infections and liver diseases. Its primary focus areas include hepatitis C virus (HCV), hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), respiratory syncytial virus (RSV), and human metapneumovirus (hMPV). Enanta offers glecaprevir, marketed as MAVYRET and MAVIRET, for chronic HCV treatment. Through a collaborative agreement with Abbott Laboratories, the company has developed paritaprevir, an HCV NS3/4A protease inhibitor. Enanta's pipeline also includes direct-acting antiviral inhibitors against HCV and other viral targets.

Accelerated Technologies, Inc. (ATI), a New York based partnership model for the creation and acceleration of cardiovascular devices.

Xanthus Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery, development, acquisition, and commercialization of small-molecule therapeutics. The company primarily focuses on creating innovative treatments for cancer and autoimmune disorders, aiming to address unmet medical needs in these areas. Through its research and development efforts, Xanthus Pharmaceuticals strives to advance therapeutic options that can improve patient outcomes and enhance the quality of care in oncology and immunology.

Asterand Bioscience is a leading global provider of high-quality human tissue and human tissue-based research solutions, primarily aimed at drug discovery scientists. Established in 2006 through the merger of Asterand, a human tissue biorepository, and Pharmagene, a drug discovery company, Asterand has a strong heritage in human tissue procurement and characterization. The company focuses on accelerating the identification and validation of drug targets while enhancing the selection of drug candidates to increase the likelihood of clinical success. With offices in Detroit, Michigan, and Royston, United Kingdom, Asterand serves pharmaceutical, biotechnology, and diagnostic companies, as well as academic institutions, offering comprehensive research services that span from target identification to compound evaluation and drug safety.

Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. The Company's scientific founders identified that interactions between specific genes and enzymes can slow the aging process, and they are developing compounds that stimulate these interactions and will be used to treat a range of diseases of aging, including metabolic disease.

Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases.

AVEO Oncology is a biopharmaceutical company that specializes in developing and commercializing targeted therapies for oncology and other unmet medical needs. The company is known for its lead product, FOTIVDA (tivozanib), an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used in the treatment of renal cell carcinoma (RCC). AVEO has completed a Phase III trial for tivozanib and is exploring its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, the company is developing other therapeutic candidates, including Ficlatuzumab, an antibody for various cancers, and AV-203, a monoclonal antibody for esophageal cancer, which has completed Phase I trials. AVEO's preclinical pipeline includes promising products aimed at treating conditions such as cachexia and pulmonary arterial hypertension. Headquartered in Boston, Massachusetts, the company was founded in 2001 and has established collaborations with various pharmaceutical firms to enhance its development efforts.

Alantos Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule drugs targeting osteoarthritis, inflammation, and type II diabetes. Founded in 2002 and based in Cambridge, Massachusetts, the company specializes in creating innovative therapies, including Dipeptidyl and Peptidase IV inhibitors. Alantos also explores various tissue remodeling pathways to address conditions such as rheumatoid arthritis, liver fibrosis, cardiovascular issues, chronic wound healing, and cancer. Through its research and development efforts, Alantos Pharmaceuticals aims to advance treatment options for patients suffering from these chronic diseases.

BioProcessors is an online platform that assists its clients in the development of drugs. BioProcessors was launched in 2000 and is based in California.

BrainGate is a path to a better way of life for severely motor-impaired individuals. Through years of advanced research, BrainGate enables these people with the ability to communicate, interact and function through thought. (view video) BrainGate's mission is to further the advancement of this life-changing technology to promote wider adoption to help impaired individuals communicate and interact with society. For instance, the Cyberkenetics BrainGate Neural Interface is currently the subject of a pilot clinical trial being conducted under an Investigational Device Exemption (IDE) from the FDA. The system is designed to restore functionality for a limited, immobile group of severely motor-impaired individuals. It is expected that people using the BrainGate System will employ a personal computer as the gateway to a range of self-directed activities. These activities may extend beyond typical computer functions (e.g., communication) to include the control of objects in the environment such as a telephone, a television and lights.

Cohesive Technologies Inc. designs, manufactures, and markets breakthrough liquid chromatography (LC) solutions for the drug discovery, pharmaceutical, contract research, and clinical diagnostic industries. The company has developed patented technologies and a wide range of chromatographic products designed to significantly improve productivity by accelerating the separation, purification, and analysis of molecules in bioanalysis. With a strong depth of knowledge in column chemistry, applications, engineering, software development, and quality management, Cohesive Technologies leads the industry in the research, development, and production of LC technologies that accelerate the pace of customers' drug discovery and development efforts.

Sirna Therapeutics is a biotechnology company focused on developing therapies based on RNA interference (RNAi), a groundbreaking scientific discovery with the potential to transform disease treatment. By harnessing the capabilities of RNAi, Sirna Therapeutics aims to create innovative solutions that address various illnesses, positioning itself at the forefront of this emerging field. The company's commitment to advancing RNAi-based therapies highlights its role in the evolving landscape of medical treatment, with the goal of improving patient outcomes through targeted interventions.

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of small molecule drugs aimed at addressing unmet medical needs in central nervous system disorders. Founded in 1993 and headquartered in San Diego, California, the company is best known for NUPLAZID (pimavanserin), which is approved for treating hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA is also advancing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive therapy for schizophrenia, both of which are currently in Phase III clinical trials. Additionally, the company is exploring the use of pimavanserin for major depressive disorder. ACADIA maintains subsidiaries in Sweden and Denmark and is focused on expanding its portfolio of drug candidates, seeking to discover innovative therapies for various neurological and psychiatric conditions.

Catalyst Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company specializes in developing innovative treatments for hemophilia and other rare bleeding disorders, utilizing its engineered subcutaneous coagulation factors to promote blood clotting. This approach aims to address the inherent limitations of traditional intravenous treatments and improve patient outcomes. Catalyst's product portfolio includes Marzeptacog alfa (activated), an advanced coagulation Factor VIIa that has completed Phase II development for hemophilia A or B with inhibitors, and Dalcinonacog alfa, a next-generation Factor IX therapy that has finished Phase IIb clinical trials for hemophilia B. Additionally, the company is working on CB 2679d-GT, an early-stage gene therapy for hemophilia B, as well as other treatments targeting dry age-related macular degeneration and systemic complement inhibitors. Catalyst Biosciences has also formed strategic collaborations with Mosaic Biosciences and Biogen to enhance its research and development efforts in these therapeutic areas. The company was founded in 2002 and has a commitment to addressing unmet medical needs in coagulation and complement disorders.

Hypnion is a neuroscience drug discovery and development company based in Worcester, Massachusetts, founded in 2000. The company specializes in creating innovative therapeutics for central nervous system disorders, particularly focusing on sleep and wake-alertness disorders, as well as circadian rhythm abnormalities. Hypnion utilizes its proprietary drug discovery platform, SCORE-2004, which measures the effects of drugs on sleep and wake parameters. This unique system enables the company to advance its research and development efforts effectively. In recognition of its innovative approach and contributions to the field, Hypnion was acquired by Eli Lilly and Company.

SuperDimension is a privately-held medical device company that specializes in developing and marketing minimally-invasive pulmonology devices aimed at diagnosing and treating distal lung disease. The company’s main product, the i·Logic System, includes both capital equipment and disposable tools designed to enhance traditional bronchoscopy techniques. These innovations allow physicians to access peripheral lung lesions and mediastinal lymph nodes, facilitating the diagnosis of previously inaccessible lung conditions at earlier stages when they may be more treatable. SuperDimension is committed to becoming a leader in the field of distal lung disease diagnosis and treatment, addressing a significant market of over 8 million patients.

As of January 27, 2004, Percutaneous Valve Technologies was acquired by Edwards Lifesciences Corp. The company develops medical devices for delivering heart valves to treat late-stage aortic stenosis. Percutaneous Valve Technologies, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.